Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma

  • Technology appraisal guidance
  • TA319
  • Published: 
Download guidance (PDF)

9 Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by Centre for Reviews and Dissemination (CRD), Centre for Health Economics (CHE), University of York:

  • Alison Eastwood, Claire McKenna, Ros Wade et al. Evidence Review Group's Final Report Ipilimumab for previously untreated unresectable malignant melanoma. December 2013.

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to give their expert views. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I. Manufacturer/sponsor:

  • Bristol-Myers Squibb

II. Professional/specialist and patient/carer groups:

  • British Association of Dermatologists

  • British Association of Skin Cancer Nurse Specialists

  • Melanoma Focus

  • Melanoma UK

  • OcuMel UK

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians

III. Other consultees:

  • Department of Health

  • NHS England

  • Welsh Government

IV. Commentator organisations (did not provide written evidence and without the right of appeal):

  • Centre for Reviews and Dissemination and Centre for Health Economics, University of York

  • Commissioning Support Appraisal Service

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Healthcare Improvement Scotland

  • Medicines and Healthcare products Regulatory Agency

  • MRC Clinical Trials Unit

  • National Clinical Guideline Centre

  • National Institute for Health Research Health Technology Assessment Programme

C. The following individuals were selected from clinical specialist and patient expert nominations from the consultees and commentators. They gave their expert personal view on ipilimumab by attending Committee discussions and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Dr Mark Harries, Consultant Medical Oncologist, nominated by organisation representing Melanoma Focus – clinical specialist

  • Dr Ruth Plummer, Consultant Medical Consultant and Clinical Professor of Experimental Cancer Medicine, nominated by organisation representing Royal College of Physicians – clinical specialist

  • Richard Jackson, nominated by organisation representing National Collaborating Centre for Cancer – patient expert (first Committee meeting only)

  • Gillian Nuttall, nominated by organisation representing Melanoma UK – patient expert (first Committee meeting only)

D. Representatives from the following manufacturer/sponsor attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Bristol-Myers Squibb